

How to Cite:

Ullah, G., Ghaffar, T., Kamal, N., & Ali, F. (2023). Frequency of hirsutism in patients with PCOS (polycystic ovary syndrome). *International Journal of Health Sciences*, 6(S9), 4623–4631.
<https://doi.org/10.53730/ijhs.v6nS9.13899>

Frequency of hirsutism in patients with PCOS (polycystic ovary syndrome)

Ghafoor Ullah

Assistant Professor, Dermatology Unit, Hayatabad Medical Complex, Peshawar, Pakistan

Tahir Ghaffar

Assistant Professor, Department of Diabetes and Endocrinology, Hayatabad Medical Complex, Peshawar, Pakistan
Corresponding author email: dr.tg.ktk@gmail.com

Nazish Kamal

Civil Hospital Shamshatto Subdivision Hassan Khel, Pakistan

Farhad Ali

Emergency Medical Officer DHQ Hospital Landikotal, Pakistan

Abstract---Objective: To estimate the prevalence of PCOS, a clinically noticeable disorder in women that causes excessive development of coarse or dark hair on the face, chest, and back in a male-like pattern, between first-degree female relatives in families with a proband who has the condition. Methods: A history of oligomenorrhea, hirsutism or biochemical proof of hyperandrogenism (raised entire or free T) and other illnesses were used to diagnose PCOS. Moreover, for better results, Study participants through PCOS (age 24.3G5.8 years, Body Mass Index 26.8G6.9 kg/m²) were used for better results. An R8-modified Ferriman-Gallwey score was used to characterize hirsutism. Results: 24% of the mothers and 32% of the sisters among the moms and sisters assessed had PCOS, respectively. Only premenopausal women who were not receiving treatment i.e., moms (35%) and sisters (40%) for PCOS were found to have the condition, which is consistent with symptoms becoming better due to hormone therapy or age. These PCOS prevalence percentages are much greater than the illness's frequency in the normal community (about 4%), which points to a considerable hereditary component. Furthermore, in comparison to female without hirsutism, hirsute female were pretty young, had greater BMIs, and also had greater amounts of circulatory androgens. However, after adjusting for age and BMI, there was no difference in the indicators of IR between the two groups. Age-related declines in hirsutism prevalence, a comparable preponderance in the

hyperandrogenemic appearance of PCOS and a decreased incidence in normal-weight female compared to obese and overweight female were also noted. Conclusion: Mothers and sisters of PCOS patients had rates of PCOS of 24% and 32%, respectively; the likelihood increased when only premenopausal women who had not received treatment were taken into account.

Keywords---polycystic ovarian syndrome, PCOS, hirsutism, hyperandrogenism, insulin resistance, obesity, oligo-ovulatory, infertility.

Introduction

Hirsutism is a significant indicator of hyperandrogenism and is usually found in polycystic ovarian syndrome (PCOS) patients. But other conditions typically associated through PCOS, including insulin resistance (IR) and abdominal obesity, also connected to the development of hirsutism in this group. However, there is a shortage of pertinent evidence. The most prevalent likely reasons of oligo-ovulatory infertility are PCOS, which affects 4 percent of unassigned reproductive-aged female [1-2]. Early research indicated that PCOS is a genetic condition, largely via published studies of affected mother-daughter relationships, sibling pairs, and combinations of conjoined twins. However, "improved" versions of the multivariate, X-linked, and dominant patterns of heredity have also been proposed. In general, the method of transmission of PCOS is yet unknown. Preceding family reports frequently had single or supplementary significant flaws, such as unpredictable or ambiguous clinical guidelines for the disease and insufficient or uncorroborated family-member data. Additionally, few studies have provided a biochemical definition of PCOS or comprised endocrine data on the probands and their relatives [3-5].

Historical family research frequently had one or more significant flaws, such as unpredictable or ambiguous clinical requirements for the disease and insufficient or uncorroborated family-member data. Additionally, few studies have provided a biochemical definition of PCOS or comprised endocrine data on the probands and their relatives [6-7]. Understanding the heredity of PCOS is crucial regardless of attempts to identify particular genetic anomalies since the disorder's inheritance appears to be complicated and multifaceted. Confirming the method of transmission will help with studies on the heredity of PCOS. These investigations will also clarify the family risk of the condition, which is crucial for counselling relatives of those afflicted. We systematically looked into the biochemical and clinical information of the families of PCOS patients in order to assess the incidence of PCOS, as described by existing endocrinology guidelines, for most first families of those with the condition [8-9].

Given that hirsutism is extremely common in the general population, adversely impacts health-related life quality or might contribute to these patients' elevated risk of coronary heart disease, identifying the hormone secretion and metabolic qualities of hirsute patients diagnosed with PCOS is a crucial component of the

disorder's administration [10]. As a result, we sought to describe the features of hirsute PCOS patients in a large cohort of individuals with this disease.

Materials and Methods

Between June 2022 to December 2022, individuals with PCOS were recruited from the Hayatabad Medical Complex, Peshawar, Pakistan. The following inclusion criteria were congruent with the recommendations: [1] hirsutism and hyperandrogenemia, and [2] indication of ovulatory dysfunction in the occurrence of [3] excluding other conditions including Cushing disorder, hypothyroidism, non-classical adrenal hyperplasia and hyperprolactinemia.

Menstrual periods longer than 45 days or, in the case of shorter cycles, a follicular phase P (P4) level less than two ng/mL in association through a monophasic BBT were considered signs of ovulatory dysfunction. A reformed Ferriman-Gallwey scale of less than six was used to describe hirsutism. Hyperandrogenemia was defined as serum overall or freed T concentrations that were above the 95% for controls. As previously described, a 17-OHP level of less than two ng/mL in the baseline follicular phase or ten ng/mL following acute ACTH stimulation ruled out nonclassical adrenal hyperplasia. Normal PRL and TSH readings ruled out hyperprolactinemia and hypothyroidism, respectively, while Cushing syndrome was ruled out by a 24hr urine-free cortisol level of less than 100 g/d if testing was clinically acceptable.

Control participants between 18 and 50 who were not using hormonal drugs were enlisted to determine the androgen levels that fell within the normal range. A quick medical examination, hirsutism grading, and blood samples were all performed on each individual. All were eumenorrheic, healthy ladies who weren't hirsute.

The sample population was divided into three groups based on the following factors: age in%20 years old, 21–30 years old; BMI in average weight (defined as having a BMI of! 25.0 kg/m²; nZ679), overweight (defined as having a BMI of 25.0-29.9 kg/m²; nZ277), and obese (defined as having a BMI of 30.0 kg/m²; nZ341); and PCOS phenomenon.

Study Protocol

We measured each woman's height, weight, and the sizes of your hips and waist. Significance was determined using analogue scales while wearing light clothing, and size was determined using a stadiometer while going barefoot. To assess obesity, the BMI was computed by dividing weight (kg) by height squared (m²). The H was measured at the level of the broadest diameter around the buttocks, and the W was determined as the lowest circumference at the level of the umbilicus. W and H were divided to determine the W/H.

The incidence of hirsutism and monthly abnormalities among the probands' mothers and sisters were inquired about, and consent to contacting all relatives regardless of past behaviour was obtained. All live mothers and sisters were attempted to be contacted once the proband gave their permission. All willing

relatives had clinical examinations using standardized forms, which included a physical exam to detect hirsutism and acne. As mentioned above, a physical examination was used to grade hirsutism. There was no additional attempt to score acne; it was just stated as present or missing. In addition to measuring height and weight, the body mass index (BMI) was computed.

Venipuncture was used to acquire serum for hormonal analysis. In premenopausal relations who are not even receiving medications that were recognized to suppress blood testosterone levels, we assessed the amounts of total T, freed T, and sexual hormone-binding globulin (SHBG). The PRL, TSH, and OHP of relations were evaluated to establish whether the clinical features for PCOS were satisfied in order that will further exclude out hyperprolactinemia, hypothyroidism, and nonclassical adrenal hyperplasia. Initial blood samples were collected within 3 and 7 following days a spontaneously bleed incident after a fasting state. The blood was examined for the presence of LH, FSH, testosterone, prolactin (PRL), DHEAS, 17a-OHP, D4-androstenedione (D4-A), sex hormone-binding globulin (SHBG), glucose, and insulin. An oral glucose tolerance test was carried out immediately after the baseline blood sample; 75 g of glucose was delivered orally, and serum glucose levels were assessed after 30, 60, 90, and 120 minutes. The volume of each ovary and the number of follicles in each ovary were measured using transvaginal ultrasound on the same day.

Table 1: Description of the phenotypes associated with PCOS

Phenotype of PCOS	Clinical manifestations of biochemical hyperandrogenemia or hyperandrogenemia	Anovulation	Ovaries with polycystic growths on trans-vaginal ultrasound
Ovulatory PCOS	+	-	+
Anovulation and hyperandrogenemia	+	+	-
Severe PCOS	+	+	+
mild PCOS	-	+	+

Hormone Assessment

After serum extraction, as previously described, entire T was determined using an in-house RIA approach. However, before the RIA, the extracted serum sample was purified using methyl chloride: isopropyl alcohol (97:3) over a Sephadex LH-20 (Pharmacia Corp., Peapack, NJ) column. Diffusion equilibrium dialysis was used to quantify SHBG using Sephadex G-25 and [3H]T as the ligand. Direct RIA was used to assess P4, PRL, 17-OHP and TSH using commercially available kits (PRL and TSH from Diagnostic Products Corp., CA; P4 and 17-OHP from CA).

An expert technician carried out transvaginal ultrasonography on each woman. The following formula was used to compute ovarian volume: ovarian volumes (p/6)! Ovarian size! Ovarian size! Ovarian breadth. Diagnostic criteria for polycystic ovaries included the existence of Twelve or maybe more follicles, each averaging 2–9 mm wide, and an increased ovarian volume (O10 cm3).

Statistical analysis

The data are continuous variables with average S.D. fluctuations that were compared among groups—utilizing a BMI and age-related covariance analysis were taken into account. Differences in hirsutism frequency between the Age, BMI, and PCOS phenotypic groups were C2 test results were evaluated. Logistic regression in Using binary analysis, it was possible to find independent predictors of hirsutism is present. Applying Pearson product moment correlation, the Ferriman-Gallwey score, its relationships, and other parameters were assessed. The following factors significantly correlated with the Ferriman-Gallwey rating: finding factors that were separately related in the Ferriman-Gallwey evaluation by applying a model of linear regression modeling and including Pearson's correlation in a step by step manner. A P value is always present 0.05 was regarded as significant. Regarding illness prevalence, statistical differences were evaluated using a two-analysis adjusted for continuity or an analysis of variance for continuous variables. P value 0.05 was used to determine statistical significance.

Results

Probands' ages varied from 13 to 48, with a mean age (8.1 year) and standard deviation (27.5) and a mean BMI (33.0 8.7 kg/cm², respectively). 86% of the probands exhibited biochemical evidence of hyperandrogenemia, and 78% had hirsutism. Blacks made up 15% of patients, while non-Hispanic whites made up 85%. Up to 67% of probands admitted to having a favorable family background of hirsutism and abnormal menstrual periods in any living first- or second-degree female relative at the time of the initial interview. Furthermore, 56% of those who came forward claimed to have at least one first-degree living female ancestor who was hirsute or had oligomenorrhea.

Additionally, (83%) of the probands gave permission to initially approach their mom, as well as sister. As to the remainder probands, consent to communication their family members was refused, they were impossible to locate, or they should have provided contact information that may have been useful. In (92%) and (88%), successful communication was made.

Regarding the degree of hirsutism, mean BMI, or severity of monthly irregularities, Probands whose families chose to engage in the study (i.e., had at minimum single female relative undergo the clinical assessment) were not considerably different from someone whose relatives opted out. Nevertheless, probands whose families took part in the research were probably younger than their rivals, perhaps as a result of the younger probands' families' wider accessibility and enthusiasm. Additionally, the relatives of white probands remained more probable than those of black probands to participate in the research.

Table 2: 1st relatives with and without PCOS, as well as controls, had average testosterone levels

Study group	Free T (ng/dL)	Total T (ng/dL)	DHEAS (ng/mL)
PCOS-related probands Mothers	1.00 ± 0.45	88.0 ± 40	1,950 ± 1,150
Mothers with PCOS	0.70 ± 0.33	70 ± 27	1,770 ± 880
Unaffected mothers Sisters	0.41 ± 0.15	50.1 ± 12.5	1,155 ± 650
Sisters with PCOS	0.90 ± 0.33	76.0 ± 28.0	2,455 ± 1,078
Unaffected sisters	0.51 ± 0.21	47.0 ± 18.0	1,314 ± 607
Healthy controls	0.43 ± 0.21	54.0 ± 19.0	1,280 ± 610

Table 3: Females with medical hyperandrogenism but still not molecular hyperandrogenism and female with both conditions exhibit different anthropometric characteristics and insulin sensitivity indicators

	Females with both medical and molecular hyperandrogenism	Females with medical but not molecular hyperandrogenism
Age	23.5 ± 5.5	26.0 ± 7
BMI	28 ± 7.0	25.1 ± 7
waist	86 ± 17.5	81.0 ± 14.5
Ferriman–Gallwey score	11.5 ± 2.7	11.0 ± 2.0
W/H	0.80 ± 0.08	0.78 ± 0.07
Insulin	14 ± 14.5	11 ± 10
Glucose	97.9 ± 36.5	100 ± 12
Glucose/insulin	10.55 ± 6.87	13.44 ± 8.67
AUC OTT	15551 ± 3294.0	15205.0 ± 2777.5
HOMA-IR	3.50 ± 4.00	2.70 ± 2.50
QUICKIE	0.34 ± 0.04	0.35 ± 0.04

Table 4: primary factors of hirsutism in female with PCOS

Variable	Odds ratio	95% CI
Age	0.966	0.944-0.988
Testosterone	1.015	1.009-1.022
Waist	1.007	1.005-1.011

Discussion

Our research revealed that there is a large familial aggregating for PCOS. There really was an average 5 to 6-fold rise in the frequency of PCOS including first female relatives of those with the correspond to the occurrence of PCOS in their overall populace. When first-degree relatives who had had postmenopausal or hormonal treatment were contrasted with those who hadn't, they showed a decreased frequency of detectable PCOS. Our statistics diverge slightly from those

recently reported. These researchers discovered that 24 percent of the total of the sister exhibited hyperandrogenemia and normal menstrual cycles, but we only saw this phenotype in 6% of the premenopausal untreated sisters. Although it is impossible to rule out the possibility that patient ethnicity or environment (such as nutrition) disparities exist, these variances may reflect differences in how PCOS is defined.

It is not known if the family accumulation of PCOS exhibits a straightforward mendelian arrangement or a additional complicated or "mixed" form of hereditary [11]. The first option might be brought on by particular and distinctive mutation(s) that disrupt the actions of insulin, gonadotropin, or steroids [12]. In the latter, several variables must interact, some of which are significantly present throughout the general populace and might contain a few crucial genes, a person's hereditary history, and ecological impacts [13]. The latter theory, which is consistent with type 2 diabetes mellitus, has received support from other researchers and us [14].

We aimed to rule out simple mendelian inheritance models that suggested a significant gene influence in light of our assumption of a complicated design of heredity for PCOS. The computation of the segregation analysis only included untreated premenopausal sister to account for the impacts of age and hormone treatment on phenotypic. We could not exclude include autosomal recessive or dominant heredity patterns in this research due to the minimal number of sisters involved. We described PCOS as a female-only condition. The much higher frequency of PCOS in moms seen in this study and previously documented aunts have a high frequency of clinical signs and grandparents point to several afflicted generations. Thus, it is improbable that PCOS is passed down in a recessive manner.

With advancing age, we noticed a gradual decrease in hirsutism prevalence [15]. Age was also independently linked with the Ferriman-Gallwey score and was a predictor of hirsutism presence [16]. We are unaware of any other research examining the connection between hirsutism and age in PCOS patients. The continual decrease in circulatory androgens in PCOS female during the menstrual cycle may cause an improvement in hirsutism with age. Given the detrimental consequences of hirsutism on patients with PCOS' quality of life, It may benefit their psychological state to inform hirsute female with PCOS about the gradual decline in hirsutism frequency with age.

Conclusion

In conclusion, we found that 40% of sisters and 35% of moms of PCOS patients will also have the condition. These results can give daughters of affected women and younger or younger sisters more accurate information about their risk of contracting the illness. The heredity of PCOS is likely more complicated, comparable to type 2 diabetes mellitus, even if we cannot rule out an autosomal or X-linked dominant manner of hereditary. The disease's molecular and clinical heterogeneity, as well as the effects of environmental variables on the morphological are both supported by this hypothesis. The genetic pathways behind PCOS remain unclear, despite recent efforts to pinpoint the gene or genes

responsible. Hence, the most informative risk factor for acquiring PCOS lacking genetic prognostic marker appears to be a healthy family background. If particular diagnostic, biochemical, and genetic risk markers for PCOS are identified, a positive family background may be more prescient. In addition to hyperandrogenemia, hirsutism is also independently linked to abdominal obesity, youth, and age. In contrast, the more extreme obesity of insulin-resistant individuals with PCOS seems to mediate the link between IR and hirsutism. Lifestyle modifications need to be the primary line of treatment for hirsutism in PCOS, given their favourable impact on circulating androgens and adiposity. Lifestyle modifications may help stop or slow the development of atherosclerosis in this group since hirsutism appears to be linked to an elevated cardiovascular risk in PCOS patients.

References

1. Somani, N., Harrison, S., & Bergfeld, W. F. (2008). The clinical evaluation of hirsutism. *Dermatologic therapy*, 21(5), 376-391.
2. Toscani, M., Migliavacca, R., de Castro, J. A. S., & Spritzer, P. M. (2007). Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. *Metabolism*, 56(7), 992-997.
3. McGovern, P. G., Legro, R. S., Myers, E. R., Barnhart, H. X., Carson, S. A., Diamond, M. P., ... & Giudice, L. C. (2007). Utility of screening for other causes of infertility in women with "known" polycystic ovary syndrome. *Fertility and sterility*, 87(2), 442-444.
4. Rapaport, F., Boisson, B., Gregor, A., Béziat, V., Boisson-Dupuis, S., Bustamante, J., ... & Patin, E. (2021). Negative selection on human genes underlying inborn errors depends on disease outcome and both the mode and mechanism of inheritance. *Proceedings of the National Academy of Sciences*, 118(3), e2001248118.
5. Franks, S., Webber, L. J., Goh, M., Valentine, A., White, D. M., Conway, G. S., ... & McCarthy, M. I. (2008). Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. *The Journal of Clinical Endocrinology & Metabolism*, 93(9), 3396-3402.
6. Stuart, H. (2003). Violence and mental illness: an overview. *World Psychiatry*, 2(2), 121.
7. Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. *Endocrine reviews*, 36(5), 487-525.
8. Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Estabrooks Hahn, S., Strecker, M. N., & Williams, J. L. (2006). A new definition of genetic counseling: National Society of Genetic Counselors' task force report. *Journal of genetic counseling*, 15(2), 77-83.
9. Wolf, W. M., Wattick, R. A., Kinkade, O. N., & Olfert, M. D. (2018). Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. *International journal of environmental research and public health*, 15(11), 2589.

10. Brady, C., Mousa, S. S., & Mousa, S. A. (2009). Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorder. *Drug, healthcare and patient safety*, 1, 9.
11. Diamanti-Kandarakis, E., Piperi, C., Argyrakopoulou, G., Spina, J., Papanastasiou, L., Bergiele, A., & Panidis, D. (2006). Polycystic ovary syndrome: the influence of environmental and genetic factors. *HORMONES-ATHENS*, 5(1), 17.
12. Chen, W., Obermayer-Pietsch, B., Hong, J. B., Melnik, B. C., Yamasaki, O., Dessinioti, C., ... & Zouboulis, C. C. (2011). Acne-associated syndromes: models for better understanding of acne pathogenesis. *Journal of the European Academy of Dermatology and Venereology*, 25(6), 637-646.
13. Rutter, M., Dunn, J., Plomin, R., Simonoff, E., Pickles, A., Maughan, B., ... & Eaves, L. (1997). Integrating nature and nurture: Implications of person-environment correlations and interactions for developmental psychopathology. *Development and psychopathology*, 9(2), 335-364.
14. McDonald, J., Jayasuriya, R., & Harris, M. F. (2012). The influence of power dynamics and trust on multidisciplinary collaboration: a qualitative case study of type 2 diabetes mellitus. *BMC Health Services Research*, 12(1), 1-10.
15. Hsu, M. I. (2013). Changes in the PCOS phenotype with age. *Steroids*, 78(8), 761-766.
16. Panidis, D., Tziomalos, K., Papadakis, E., Chatzis, P., Kandaraki, E. A., Tsourdi, E. A., ... & Katsikis, I. (2013). The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. *Eur J Endocrinol*, 168(6), 871-877.